Novartis Q3 operating income up 6% on new drug sales

Avidity Biosciences

28/10/2025 06:10

FRANKFURT, Oct 28 (Reuters) - Swiss drugmaker Novartis NOVN.S, on a deal-making spree this year, reported a gain in operating income of 6% as growth of its new drugs made up for stagnant revenue from established heart drug Entresto.

Third-quarter operating income, adjusted for special items, rose to $5.46 billion, slightly above consensus numbers cited by analysts of $5.4 billion.

 (Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London, Editing by Friederike Heine)

 ((ludwig.burger@thomsonreuters.com;))